$KPTI
Karyopharm Therapeutics Inc.

2018 Q2 Form 10-Q Financial Statement

#000119312518159200 Filed on May 10, 2018

View on sec.gov

Income Statement

Concept 2018 Q2 2018 Q1 2017 Q1
Revenue $19.89M $10.00M $68.00K
YoY Change 662933.33% 14605.88%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $9.490M $7.620M $6.260M
YoY Change 42.92% 21.73% 12.79%
% of Gross Profit
Research & Development $44.73M $41.32M $24.08M
YoY Change 93.49% 71.58% 10.5%
% of Gross Profit
Depreciation & Amortization $180.0K $170.0K $180.0K
YoY Change 0.0% -5.56% 0.0%
% of Gross Profit
Operating Expenses $54.22M $48.94M $30.35M
YoY Change 82.23% 61.27% 10.96%
Operating Profit -$34.33M -$38.94M -$30.28M
YoY Change 15.39% 28.61% 10.71%
Interest Expense $650.0K $510.0K $400.0K
YoY Change 58.54% 27.5% 37.93%
% of Operating Profit
Other Income/Expense, Net $660.0K $495.0K $385.0K
YoY Change 72.32% 28.57% 32.76%
Pretax Income -$33.67M -$38.45M -$29.89M
YoY Change 14.65% 28.61% 10.48%
Income Tax -$17.00K $12.00K $23.00K
% Of Pretax Income
Net Earnings -$33.66M -$38.46M -$29.92M
YoY Change 14.52% 28.55% 10.56%
Net Earnings / Revenue -169.2% -384.59% -43995.59%
Basic Earnings Per Share
Diluted Earnings Per Share -$600.1K -$775.4K -$714.3K
COMMON SHARES
Basic Shares Outstanding 49.85M shares 49.65M shares 41.90M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q2 2018 Q1 2017 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $241.1M $130.9M $109.9M
YoY Change 68.03% 19.11% -19.43%
Cash & Equivalents $119.0M $37.50M $25.58M
Short-Term Investments $122.2M $93.40M $84.30M
Other Short-Term Assets $3.400M $2.400M $2.300M
YoY Change 47.83% 4.35% 35.29%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $244.6M $133.3M $112.2M
YoY Change 67.82% 18.79% -18.76%
LONG-TERM ASSETS
Property, Plant & Equipment $2.611M $2.454M $2.654M
YoY Change 5.58% -7.54% -20.61%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $8.800M $10.30M $40.30M
YoY Change -76.41% -74.44% -19.72%
Other Assets $600.0K $300.0K $15.00K
YoY Change 100.0% 1900.0% -97.0%
Total Long-Term Assets $12.03M $13.06M $43.21M
YoY Change -69.94% -69.77% -19.98%
TOTAL ASSETS
Total Short-Term Assets $244.6M $133.3M $112.2M
Total Long-Term Assets $12.03M $13.06M $43.21M
Total Assets $256.6M $146.4M $155.4M
YoY Change 38.14% -5.83% -19.1%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.794M $4.949M $4.245M
YoY Change 16.85% 16.58% 3.31%
Accrued Expenses $22.97M $21.55M $10.74M
YoY Change 78.39% 100.61% 24.13%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $36.54M $46.73M $15.48M
YoY Change 108.58% 201.88% 17.09%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $6.600M $4.100M $1.600M
YoY Change 340.0% 156.25% -15.79%
Total Long-Term Liabilities $6.600M $4.100M $1.600M
YoY Change 340.0% 156.25% -15.79%
TOTAL LIABILITIES
Total Short-Term Liabilities $36.54M $46.73M $15.48M
Total Long-Term Liabilities $6.600M $4.100M $1.600M
Total Liabilities $43.12M $50.84M $17.07M
YoY Change 126.5% 197.82% 13.07%
SHAREHOLDERS EQUITY
Retained Earnings -$567.5M -$533.8M -$396.3M
YoY Change 33.31% 34.7% 39.74%
Common Stock $781.2M $629.6M $534.8M
YoY Change 31.84% 17.72% 16.14%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $213.5M $95.53M $138.4M
YoY Change
Total Liabilities & Shareholders Equity $256.6M $146.4M $155.4M
YoY Change 38.14% -5.83% -19.1%

Cashflow Statement

Concept 2018 Q2 2018 Q1 2017 Q1
OPERATING ACTIVITIES
Net Income -$33.66M -$38.46M -$29.92M
YoY Change 14.52% 28.55% 10.56%
Depreciation, Depletion And Amortization $180.0K $170.0K $180.0K
YoY Change 0.0% -5.56% 0.0%
Cash From Operating Activities -$37.63M -$34.65M -$24.71M
YoY Change 73.25% 40.23% 6.65%
INVESTING ACTIVITIES
Capital Expenditures -$400.0K $382.0K
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$27.21M $2.870M $550.0K
YoY Change 2286.84% 421.82% -91.9%
Cash From Investing Activities -$27.60M $2.484M $550.0K
YoY Change 2321.05% 351.64% -91.85%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 147.1M 429.0K 60.00K
YoY Change 179.87% 615.0% -70.0%
NET CHANGE
Cash From Operating Activities -37.63M -34.65M -24.71M
Cash From Investing Activities -27.60M 2.484M 550.0K
Cash From Financing Activities 147.1M 429.0K 60.00K
Net Change In Cash 81.90M -31.70M -24.09M
YoY Change 175.66% 31.6% 48.5%
FREE CASH FLOW
Cash From Operating Activities -$37.63M -$34.65M -$24.71M
Capital Expenditures -$400.0K $382.0K
Free Cash Flow -$37.23M -$35.03M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q1 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
364000
CY2018Q1 us-gaap Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Greater Than Or Equal To One Year
AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear
0 Securities
CY2014Q4 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
3681 sqft
CY2014Q4 kpti Operating Lease Scheduled Rent Payments Due
OperatingLeaseScheduledRentPaymentsDue
374000
CY2014Q4 kpti Operating Lease Scheduled Rent Payments Due
OperatingLeaseScheduledRentPaymentsDue
461000
CY2018Q1 us-gaap Security Deposit
SecurityDeposit
200000
CY2018Q1 kpti Additional Area Included In Operating Lease After Amendment
AdditionalAreaIncludedInOperatingLeaseAfterAmendment
15976 sqft
CY2018Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
49849972 shares
CY2014Q1 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
29933 sqft
CY2014Q1 us-gaap Security Deposit
SecurityDeposit
400000
CY2017Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
26056000
CY2018Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
21545000
CY2018Q1 us-gaap Assets Current
AssetsCurrent
133313000
CY2018Q1 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
119283000
CY2018Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1764000
CY2018Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2727000
CY2018Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
629610000
CY2018Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
4949000
CY2018Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-286000
CY2018Q1 us-gaap Assets
Assets
146373000
CY2018Q1 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
2000
CY2018Q1 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
91549000
CY2018Q1 us-gaap Available For Sale Securities
AvailableForSaleSecurities
103732000
CY2018Q1 us-gaap Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year
AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear
49 Securities
CY2018Q1 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
104094000
CY2018Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
37499000
CY2018Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
37791000
CY2018Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2018Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
285000
CY2018Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2454000
CY2018Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
333000
CY2018Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2018Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2018Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2396000
CY2018Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2018Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2018Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
49670328 shares
CY2018Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2018Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
49670328 shares
CY2018Q1 us-gaap Common Stock Value
CommonStockValue
5000
CY2018Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
19729000
CY2018Q1 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
1918000
CY2018Q1 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
178000
CY2018Q1 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
2192000
CY2018Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2518000
CY2018Q1 us-gaap Liabilities
Liabilities
50844000
CY2018Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
146373000
CY2018Q1 us-gaap Liabilities Current
LiabilitiesCurrent
46734000
CY2018Q1 us-gaap Long Term Investments
LongTermInvestments
10314000
CY2018Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5181000
CY2018Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
292000
CY2018Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-533800000
CY2018Q1 us-gaap Short Term Investments
ShortTermInvestments
93418000
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
95529000
CY2018Q1 kpti Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
16978000
CY2014Q4 kpti Additional Area Included In Operating Lease After Amendment
AdditionalAreaIncludedInOperatingLeaseAfterAmendment
16234 sqft
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
50142000
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
21445000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
148423000
CY2017Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
148673000
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
972000
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2558000
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
625017000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5665000
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-217000
CY2017Q4 us-gaap Assets
Assets
180294000
CY2017Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
3000
CY2017Q4 us-gaap Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Greater Than Or Equal To One Year
AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear
0 Securities
CY2017Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
256000
CY2017Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
96623000
CY2017Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
106868000
CY2017Q4 us-gaap Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year
AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear
54 Securities
CY2017Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
107121000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
68997000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
69487000
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
49533150 shares
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
49533150 shares
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
5000
CY2017Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
21921000
CY2017Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
1363000
CY2017Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
303000
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3982000
CY2017Q4 us-gaap Liabilities
Liabilities
50830000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
180294000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
49467000
CY2017Q4 us-gaap Long Term Investments
LongTermInvestments
29396000
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
293000
CY2017Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
133000
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1754000
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2185000
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4743000
CY2017Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
200000
CY2017Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
290000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-495341000
CY2015Q1 kpti Operating Leases Allowance For Improvements
OperatingLeasesAllowanceForImprovements
1616000
CY2017Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-267000
CY2017Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-24086000
CY2017Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-29847000
CY2017Q1 us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
15000
CY2017Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
183000
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.71
CY2018Q1 dei Amendment Flag
AmendmentFlag
false
CY2018Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-160000
CY2018Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
56000
CY2017Q4 us-gaap Short Term Investments
ShortTermInvestments
77472000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
129464000
CY2017Q4 kpti Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
16198000
CY2014Q4 us-gaap Lessee Leasing Arrangements Operating Leases Term Of Contract
LesseeLeasingArrangementsOperatingLeasesTermOfContract
P5Y
CY2017Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16000
CY2017Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6264000
CY2017Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-29894000
CY2017Q1 us-gaap Increase Decrease In Prepaid Rent
IncreaseDecreaseInPrepaidRent
69000
CY2017Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
23000
CY2017Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-522000
CY2017Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-498000
CY2017Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
61000
CY2017Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
400000
CY2017Q1 us-gaap License And Services Revenue
LicenseAndServicesRevenue
68000
CY2017Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
549000
CY2017Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-24708000
CY2017Q1 us-gaap Operating Expenses
OperatingExpenses
30347000
CY2017Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
57000
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-29917000
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-30279000
CY2017Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
385000
CY2017Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
11000
CY2017Q1 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
301000
CY2017Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
59000
CY2017Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-15000
CY2017Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
25075000
CY2017Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
57000
CY2017Q1 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
25624000
CY2017Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24083000
CY2017Q1 us-gaap Share Based Compensation
ShareBasedCompensation
5909000
CY2017Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
41894796 shares
CY2018Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
12000
CY2018Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-773000
CY2018Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-31696000
CY2018Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-38528000
CY2018Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2018Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
169000
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.78
CY2018Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2018Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
CY2018Q1 dei Document Type
DocumentType
10-Q
CY2018Q1 dei Document Period End Date
DocumentPeriodEndDate
2018-03-31
CY2018Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
43000
CY2018Q1 dei Entity Registrant Name
EntityRegistrantName
KARYOPHARM THERAPEUTICS INC.
CY2018Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001503802
CY2018Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2018Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7621000
CY2018Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-38447000
CY2018Q1 us-gaap Increase Decrease In Prepaid Rent
IncreaseDecreaseInPrepaidRent
-430000
CY2018Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
295000
CY2018Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
638000
CY2018Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
509000
CY2018Q1 us-gaap License And Services Revenue
LicenseAndServicesRevenue
10000000
CY2018Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
2484000
CY2018Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-34652000
CY2018Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
24736000
CY2018Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
382000
CY2018Q1 us-gaap Operating Expenses
OperatingExpenses
48942000
CY2018Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
429000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-38459000
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-38942000
CY2018Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
495000
CY2018Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
39000
CY2018Q1 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
373000
CY2018Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-108000
CY2018Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-14000
CY2018Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
429000
CY2018Q1 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
27602000
CY2018Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
41321000
CY2018Q1 us-gaap Share Based Compensation
ShareBasedCompensation
4164000
CY2018Q1 dei Trading Symbol
TradingSymbol
KPTI
CY2018Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
49602809 shares
CY2018Q1 kpti Operating Leases Allowance For Improvements
OperatingLeasesAllowanceForImprovements
438000

Files In Submission

Name View Source Status
0001193125-18-159200-index-headers.html Edgar Link pending
0001193125-18-159200-index.html Edgar Link pending
0001193125-18-159200.txt Edgar Link pending
0001193125-18-159200-xbrl.zip Edgar Link pending
d575436d10q.htm Edgar Link pending
d575436dex101.htm Edgar Link pending
d575436dex102.htm Edgar Link pending
d575436dex103.htm Edgar Link pending
d575436dex311.htm Edgar Link pending
d575436dex312.htm Edgar Link pending
d575436dex321.htm Edgar Link pending
d575436dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g575436g0427074812004.jpg Edgar Link pending
kpti-20180331.xml Edgar Link completed
kpti-20180331.xsd Edgar Link pending
kpti-20180331_cal.xml Edgar Link unprocessable
kpti-20180331_def.xml Edgar Link unprocessable
kpti-20180331_lab.xml Edgar Link unprocessable
kpti-20180331_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending